County Durham and Darlington
Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on **Thursday 7th September 2017**

Classification of products:

G **Green drug** - Can be initiated and prescribed in all care settings O- Second line / alternative green drug

G+ **Green+ drug** Specialist initiation / recommendation. Can be recommended by a specialist for initiation in primary care; or be initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.

A **Amber drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care

R **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as "hospital only" drugs

✕ **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within County Durham & Darlington.

Not Reviewed - Drugs that haven't been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in County Durham & Darlington.

Unclassed Drug - Drugs that do not fall into one of the above categories

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
None				
2) New Requests				
None				
3) New formulations & extensions to use				
None				
5) Products considered by NICE				
TA446 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA447 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA448 Etelcalcetide for treating secondary hyperparathyroidism	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease.	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA450 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA451 Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA452 Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)		✓		The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA453 Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)		✓		The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA454 Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)		✓		The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA456 Ustekinumab for moderately to severely active Crohn's disease after previous treatment	✓ R			The formulary will reflect the TAG – CCG is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA457 Carfilzomib for previously treated multiple myeloma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
T458 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA459 Collagenase clostridium histolyticum for treating Dupuytren's contracture	✓ R			The formulary will reflect the TAG – CCG is the responsible commissioner.
TA460 Adalimumab and dexamethasone for treating non-infectious uveitis	✓ R			The formulary will reflect the TAG – CCG is the responsible commissioner.
TA461 Roflumilast for treating chronic obstructive pulmonary disease	✓ G+			The formulary will reflect the TAG – CCG is the responsible commissioner.
TA462 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
6) Northern (NHS) Treatment Advisory Group (N-TAG)				
Rituximab Biosimilars	✓ R			The Northern (NHS) Treatment Advisory Group recommends the use of rituximab biosimilars as an option for use in adults where the originator product (MabThera®) would normally be prescribed.
Sodium oxybate (Xyrem®) in the management of narcolepsy with cataplexy in adult patients	✓ R			Treatment Advisory Group only recommends the use of sodium oxybate in adult patients who have received and benefited from treatment with sodium oxybate as commissioned by NHS England. i.e. continuing treatment for those >19 years old. The strict NHS England criteria for starting and stopping must continue to be followed. The use of sodium oxybate in new adult patients is not recommended.
Pitolisant (Wakix®) for the treatment of narcolepsy with or without cataplexy in adults.		✓		The Northern (NHS) Treatment Advisory Group does not recommend the use of Pitolisant.

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Qutenza® (capsaicin) cutaneous patch for neuropathic pain (updated)	✓ R			The Northern (NHS) Treatment Advisory Group considered an appraisal of the use of Qutenza® (capsaicin) patches for neuropathic pain and recommends use of Qutenza® as a fourth line agent for neuropathic pain and in line with the regionally agreed pathway. This patch will need to be administered by a specialist and under a local anaesthetic to reduce potential application related discomfort patients will be keen to ensure that it is of benefit.
7) Appeals against earlier decisions by the APC				
None				
8) Miscellaneous decisions by the APC				
Phenindione 50mg tablets				Strength discontinued by manufacturer so removed from formulary.
Atorvastatin 10mg and 20mg chewable tablets	✓ Go			More cost effective than simvastatin or atorvastatin liquid. For use in patients with swallowing difficulties needed a statin. To include note to be used instead of simvastatin or atorvastatin oral suspension
Benperidol 0.25mg tablets	✓ G+			Only licensed preparation for the control of deviant anti-social sexual behaviour. Added to formulary as per TEWV Safe Transfer of Prescribing document
Fluphenazine Decanoate (Modecate®) Injection				Being discontinued from 2018. Add note to formulary that no new patients to be started on it as being discontinued from 2018.
Enoxaparin Injection				Now labelled in units and mg so added strength in units and mg to formulary.
Trimipramine		✓		Added to DNP List
Meningitis Vaccine				Clarify that it is the ACWY vaccine that is not prescribable on the NHS for travel purposes.
Combined Hep A/Hep B vaccine				Added to DNP list as Hep B not prescribable on the NHS for travel purposes. The APC noted the current supply shortages with Hep B vaccine and that Public Health England have issued guidance to mitigate the shortages and the combined vaccine is recommended in certain circumstances to help manage the shortages currently. Prescribers are advised to follow Public Health England until supply issues are resolved.

The following guidelines were presented to and approved at the September 2017 meeting of the APC:

- Adult Vitamin D – Quick Reference Guide
- Patient Decision Aids Resource
- Erectile Dysfunction Guidelines
- Opioid Prescribing for Persistent (Non-Cancer) Pain in Adults
- Key Messages: For Pain Management Scenarios
- Pharmacological Treatment of Neuropathic Pain

The following Green+ drug information leaflets were presented to and approved at the September 2017 meeting of the APC:

- Nil

The following shared care guidelines were presented to and approved at the September 2017 meeting of the APC:

- Lithium (TEWV)